SFPIA
ATRA icon

Stevens First Principles Investment Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Stevens First Principles Investment Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-12
Closed -$16K – 189
2015
Q2 		$16K Buy
+12
New +$13.8K 0.01% 178

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Stevens First Principles Investment Advisors's ATRA Position: Q3 2015 in Review

Stevens First Principles Investment Advisors sold out of Atara Biotherapeutics (ATRA) in Q3 2015, closing a stake of 12 shares — an estimated $16K sold.

Stevens First Principles Investment Advisors first reported a position in ATRA in Q2 2015 and held it in 1 quarter. The position peaked at $16K in Q2 2015. 90 funds tracked by Wall St. Rank hold ATRA as of Q3 2015.

  • Stevens First Principles Investment Advisors reported no remaining Atara Biotherapeutics position as of Q3 2015 after selling out during the quarter.
  • Stevens First Principles Investment Advisors sold 12 Atara Biotherapeutics shares in Q3 2015, an estimated $16K.
  • Stevens First Principles Investment Advisors first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 1 quarter.
  • Stevens First Principles Investment Advisors's Atara Biotherapeutics position peaked at $16K in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2015.

Based on Stevens First Principles Investment Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.